File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Use of hormone replacement therapy in the Hong Kong public health sector after the Women's Health Initiative trial

TitleUse of hormone replacement therapy in the Hong Kong public health sector after the Women's Health Initiative trial
Authors
KeywordsHong Kong
Hormone replacement therapy
Menopause
Women
Issue Date2005
PublisherElsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/maturitas
Citation
Maturitas, 2005, v. 52 n. 3-4, p. 277-285 How to Cite?
AbstractObjectives: To determine the impact of Women Health Initiative (WHI) trial on the use of hormone replacement therapy (HRT) in the Hong Kong public health sector. Methods: The central prescription database of the Hospital Authority was used to describe the half-yearly trend in the use of HRT between July 2000 and December 2003. The data of hysterectomy was retrieved from another clinical database. Results: Before the publication of the WHI trial in July 2002, conjugated equine estrogens (CEE) and its related products dominated HRT prescribing. Relative to the first half of 2002, there was an immediate and substantial decline by 43.5% in the prescriptions of combined CEE/progestogen products and a modest decline by 22.4% in the prescriptions of CEE-alone therapy in the second half of 2002. In the first half of 2003, a decline in the prescriptions of all HRT preparations except raloxifene was observed. However, in the second half of 2003, there were no more declines in overall HRT users. Relative to the first half of 2002, the decline in the overall HRT users in the first half of 2003 was more than 46% in women aged 50-69. The decline was greater in women with a history of hysterectomy (60.3%) than women without (38.6%), but was similar between gynaecology specialty (41.7%) and non-gynaecology specialty (43.9%). Conclusions: Similar to the U.S., an immediate and substantial decline in the use of CEE and its related products was observed in Hong Kong after the publication of the WHI trial. © 2005 Elsevier Ireland Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/87285
ISSN
2015 Impact Factor: 3.12
2015 SCImago Journal Rankings: 1.107
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLeung, KYen_HK
dc.contributor.authorLing, Men_HK
dc.contributor.authorTang, GWKen_HK
dc.date.accessioned2010-09-06T09:27:43Z-
dc.date.available2010-09-06T09:27:43Z-
dc.date.issued2005en_HK
dc.identifier.citationMaturitas, 2005, v. 52 n. 3-4, p. 277-285en_HK
dc.identifier.issn0378-5122en_HK
dc.identifier.urihttp://hdl.handle.net/10722/87285-
dc.description.abstractObjectives: To determine the impact of Women Health Initiative (WHI) trial on the use of hormone replacement therapy (HRT) in the Hong Kong public health sector. Methods: The central prescription database of the Hospital Authority was used to describe the half-yearly trend in the use of HRT between July 2000 and December 2003. The data of hysterectomy was retrieved from another clinical database. Results: Before the publication of the WHI trial in July 2002, conjugated equine estrogens (CEE) and its related products dominated HRT prescribing. Relative to the first half of 2002, there was an immediate and substantial decline by 43.5% in the prescriptions of combined CEE/progestogen products and a modest decline by 22.4% in the prescriptions of CEE-alone therapy in the second half of 2002. In the first half of 2003, a decline in the prescriptions of all HRT preparations except raloxifene was observed. However, in the second half of 2003, there were no more declines in overall HRT users. Relative to the first half of 2002, the decline in the overall HRT users in the first half of 2003 was more than 46% in women aged 50-69. The decline was greater in women with a history of hysterectomy (60.3%) than women without (38.6%), but was similar between gynaecology specialty (41.7%) and non-gynaecology specialty (43.9%). Conclusions: Similar to the U.S., an immediate and substantial decline in the use of CEE and its related products was observed in Hong Kong after the publication of the WHI trial. © 2005 Elsevier Ireland Ltd. All rights reserved.en_HK
dc.languageengen_HK
dc.publisherElsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/maturitasen_HK
dc.relation.ispartofMaturitasen_HK
dc.rightsMaturitas. Copyright © Elsevier Ireland Ltd.en_HK
dc.subjectHong Kongen_HK
dc.subjectHormone replacement therapyen_HK
dc.subjectMenopauseen_HK
dc.subjectWomenen_HK
dc.titleUse of hormone replacement therapy in the Hong Kong public health sector after the Women's Health Initiative trialen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0378-5122&volume=52&spage=277&epage=285&date=2005&atitle=Use+of+hormone+replacement+therapy+in+the+Hong+Kong+public+health+sector+after+the+women%27s+health+initiative+trialen_HK
dc.identifier.emailTang, GWK:gwktang@hkucc.hku.hken_HK
dc.identifier.authorityTang, GWK=rp00328en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.maturitas.2005.04.008en_HK
dc.identifier.pmid15950409-
dc.identifier.scopuseid_2-s2.0-27644456345en_HK
dc.identifier.hkuros117245en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-27644456345&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume52en_HK
dc.identifier.issue3-4en_HK
dc.identifier.spage277en_HK
dc.identifier.epage285en_HK
dc.identifier.isiWOS:000233625300011-
dc.publisher.placeIrelanden_HK
dc.identifier.scopusauthoridLeung, KY=8247106900en_HK
dc.identifier.scopusauthoridLing, M=16552664600en_HK
dc.identifier.scopusauthoridTang, GWK=7401633864en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats